Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
regadenoson
Overview
What is LEXISCAN?
Regadenoson is an A adenosine receptor agonist that is a coronary vasodilator []. Regadenoson is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1-pyrazol-1-yl]-, monohydrate. Its structural formula is:
The molecular formula for regadenoson is CHNO• HO and its molecular weight is 408.37.
LEXISCAN is a sterile, nonpyrogenic solution for intravenous injection. The solution is clear and colorless. Each 1 mL in the 5 mL pre-filled syringe contains 0.084 mg of regadenoson monohydrate, corresponding to 0.08 mg regadenoson on an anhydrous basis, 10.9 mg dibasic sodium phosphate dihydrate or 8.7 mg dibasic sodium phosphate anhydrous, 5.4 mg monobasic sodium phosphate monohydrate, 150 mg propylene glycol, 1 mg edetate disodium dihydrate, and Water for Injection, with pH between 6.3 and 7.7.
What does LEXISCAN look like?


What are the available doses of LEXISCAN?
What should I talk to my health care provider before I take LEXISCAN?
How should I use LEXISCAN?
LEXISCAN (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.
The recommended intravenous dose of LEXISCAN is 5 mL (0.4 mg regadenoson)
•
• [].
• Administer LEXISCAN as a rapid (approximately 10 seconds) injection into a peripheral vein using a 22 gauge or larger catheter or needle.
• Administer a 5 mL saline flush immediately after the injection of LEXISCAN.
• Administer the radionuclide myocardial perfusion imaging agent 10–20 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as LEXISCAN.
What interacts with LEXISCAN?
Sorry No Records found
What are the warnings of LEXISCAN?
Sorry No Records found
What are the precautions of LEXISCAN?
Sorry No Records found
What are the side effects of LEXISCAN?
Sorry No records found
What should I look out for while using LEXISCAN?
Do not administer LEXISCAN to patients with:
unless these patients have a functioning artificial pacemaker [].
What might happen if I take too much LEXISCAN?
LEXISCAN overdosage may result in serious reactions []. In a study of healthy volunteers, symptoms of flushing, dizziness and increased heart rate were assessed as intolerable at LEXISCAN doses greater than 0.02 mg/kg.
How should I store and handle LEXISCAN?
Storage ConditionsStore at or below 25°C (77°F); however, brief exposure up to 40°C (104°F) does not adversely affect the product. Avoid excessive heat. Protect from freezing. Protect from light. Sterile, Nonpyrogenic, Preservative-free, PVC-free, DEHP-free.The container closure is not made with natural rubber latex.Storage ConditionsStore at or below 25°C (77°F); however, brief exposure up to 40°C (104°F) does not adversely affect the product. Avoid excessive heat. Protect from freezing. Protect from light. Sterile, Nonpyrogenic, Preservative-free, PVC-free, DEHP-free.The container closure is not made with natural rubber latex.Storage ConditionsStore at or below 25°C (77°F); however, brief exposure up to 40°C (104°F) does not adversely affect the product. Avoid excessive heat. Protect from freezing. Protect from light. Sterile, Nonpyrogenic, Preservative-free, PVC-free, DEHP-free.The container closure is not made with natural rubber latex.Storage ConditionsStore at or below 25°C (77°F); however, brief exposure up to 40°C (104°F) does not adversely affect the product. Avoid excessive heat. Protect from freezing. Protect from light. Sterile, Nonpyrogenic, Preservative-free, PVC-free, DEHP-free.The container closure is not made with natural rubber latex.Storage ConditionsStore at or below 25°C (77°F); however, brief exposure up to 40°C (104°F) does not adversely affect the product. Avoid excessive heat. Protect from freezing. Protect from light. Sterile, Nonpyrogenic, Preservative-free, PVC-free, DEHP-free.The container closure is not made with natural rubber latex.LEXISCAN is supplied as a sterile, preservative-free solution containing 0.08 mg/mL regadenoson in the following package:
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Regadenoson is a low affinity agonist (K ≈ 1.3 µM) for the Aadenosine receptor, with at least 10-fold lower affinity for the A adenosine receptor (K > 16.5 µM), and weak, if any, affinity for the A and A adenosine receptors. Activation of the A adenosine receptor by regadenoson produces coronary vasodilation and increases coronary blood flow (CBF).
Non-Clinical Toxicology
Do not administer LEXISCAN to patients with:unless these patients have a functioning artificial pacemaker [].
Because of possible effects on blood pressure, Methylphenidate HCl Extended-Release Capsules CD should be used cautiously with pressor agents.
Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (e.g., phenobarbital, phenytoin, primidone), phenylbutazone and some antidepressants (tricyclics and selective serotonin reuptake inhibitors). Downward dose adjustment of these drugs may be required when given concomitantly with methylphenidate. It may be necessary to adjust the dosage and monitor plasma drug concentrations (or, in the case of coumarin, coagulation times), when initiating or discontinuing concomitant methylphenidate.
In theory, there is a possibility that the clearance of methylphenidate might be affected by urinary pH, either being increased with acidifying agents or decreased with alkalizing agents. This should be considered when methylphenidate is given in combination with agents that alter urinary pH.
Fatal and nonfatal myocardial infarction (MI), ventricular arrhythmias, and cardiac arrest have occurred following LEXISCAN injection. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reactions to LEXISCAN. Cardiac resuscitation equipment and trained staff should be available before administering LEXISCAN. If serious reactions to LEXISCAN occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by LEXISCAN [].
The following adverse reactions are discussed in more detail in other sections of the labeling.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).